Interplay of infection and vaccination in long-term protection from COVID-19

Affiliations

¹ Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
² Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Electronic address: jennifer.juno@unimelb.edu.au.

Comment

Hyon-Xhi Tan et al. Lancet Infect Dis. 2022 Jun.

. 2022 Jun;22(6):744-745.

doi: 10.1016/S1473-3099(22)00210-9. Epub 2022 Apr 1.

¹ Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
² Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Electronic address: jennifer.juno@unimelb.edu.au.

No abstract available

Conflict of interest statement

We declare no competing interests.

Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P, Ballin M, Nordström A. Nordström P, et al. Lancet Infect Dis. 2022 Jun;22(6):781-790. doi: 10.1016/S1473-3099(22)00143-8. Epub 2022 Apr 1. Lancet Infect Dis. 2022. PMID: 35366962 Free PMC article.

1. Nordström P, Ballin M, Nordström A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022 doi: 10.1016/S1473-3099(22)00143-8. published online March 31. - DOI - PMC - PubMed
1. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 omicron variant. Nat Med. 2022 doi: 10.1038/s41591-021-01676-0. published online Jan 19. - DOI - PMC - PubMed
1. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022 doi: 10.1038/s41591-022-01704-7. published online Jan 20. - DOI - PMC - PubMed
1. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2:e240–e249. - PMC - PubMed
1. Harrington WE, Trakhimets O, Andrade DV, et al. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. Cell Rep Med. 2021;2 - PMC - PubMed